BCL2 and ovarian carcinoma: We have previously shown on large groups of patients that the TP53 accumulation status determined the clinical significance of altered expression of some genes, like BAX, BCL2 or ERBB2, and polymorphisms in others (AR, FSHR) in ovarian cancer patients [10, 11, 17, 18].